Recursion Pharmaceuticals (NASDAQ:RXRX) Trading 9.8% Higher – Here’s Why

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)’s stock price rose 9.8% on Wednesday . The company traded as high as $3.36 and last traded at $3.3940. Approximately 17,051,622 shares traded hands during trading, a decline of 6% from the average daily volume of 18,116,604 shares. The stock had previously closed at $3.09.

Analysts Set New Price Targets

A number of research analysts recently commented on RXRX shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research note on Friday, July 17th. Wall Street Zen downgraded shares of Recursion Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Saturday, August 8th. JPMorgan Chase & Co. reduced their price target on shares of Recursion Pharmaceuticals from $11.00 to $10.00 and set an “overweight” rating on the stock in a research report on Thursday, April 30th. Morgan Stanley set a $5.30 price objective on shares of Recursion Pharmaceuticals in a research note on Monday. Finally, Needham & Company LLC restated a “buy” rating and set a $8.00 target price on shares of Recursion Pharmaceuticals in a research note on Thursday, May 7th. Two analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $8.06.

Recursion Pharmaceuticals Price Performance

The business’s fifty day moving average price is $3.28 and its 200 day moving average price is $3.38. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.03 and a quick ratio of 5.03. The stock has a market cap of $1.81 billion, a P/E ratio of -3.26 and a beta of 1.03.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.01). The company had revenue of $7.67 million for the quarter, compared to the consensus estimate of $10.97 million. Recursion Pharmaceuticals had a negative net margin of 945.94% and a negative return on equity of 50.41%. During the same period last year, the firm posted ($0.41) earnings per share. Sell-side analysts forecast that Recursion Pharmaceuticals, Inc. will post -0.9 EPS for the current fiscal year.

Insider Transactions at Recursion Pharmaceuticals

In other news, CEO Najat Khan sold 23,588 shares of the business’s stock in a transaction dated Friday, June 5th. The stock was sold at an average price of $3.58, for a total transaction of $84,445.04. Following the sale, the chief executive officer directly owned 2,175,796 shares in the company, valued at approximately $7,789,349.68. The trade was a 1.07% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Blake Borgeson sold 40,000 shares of the company’s stock in a transaction that occurred on Tuesday, July 7th. The shares were sold at an average price of $3.96, for a total value of $158,400.00. Following the completion of the transaction, the director directly owned 6,218,287 shares of the company’s stock, valued at $24,624,416.52. This represents a 0.64% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 131,937 shares of company stock valued at $478,874. Insiders own 6.65% of the company’s stock.

Institutional Investors Weigh In On Recursion Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the business. International Assets Investment Management LLC bought a new position in shares of Recursion Pharmaceuticals during the fourth quarter valued at $31,000. Integral Investment Advisors Inc. bought a new stake in shares of Recursion Pharmaceuticals in the first quarter worth $39,000. Sequoia Financial Advisors LLC acquired a new stake in Recursion Pharmaceuticals in the fourth quarter valued at $41,000. MQS Management LLC acquired a new stake in Recursion Pharmaceuticals in the first quarter valued at $41,000. Finally, Fund Advisors of America Inc FL bought a new position in Recursion Pharmaceuticals during the 2nd quarter worth $45,000. 89.06% of the stock is currently owned by institutional investors and hedge funds.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.